A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells

Vaccine

Volumn 27, Issue 28, 2009, Pages 3735-3743

  Yamanaka, Atsushi ^a,b,c   Konishi, Eiji ^a,b  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AIRLANGGA UNIVERSITY   (Indonesia)

Author keywords

Dengue; Vaccine; Viremia

Indexed keywords

D2EP PROTEIN VACCINE; DENGUE VACCINE; DNA VACCINE; HYPERIMMUNE GLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D1 4G2; MONOCLONAL ANTIBODY D2 II 6D6; MONOCLONAL ANTIBODY D2 III 1B6; MONOCLONAL ANTIBODY D2 V 10F1; PCD2ME DNA VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CELL STRAIN K 562; CONTROLLED STUDY; DDY MOUSE; DEATH; DENGUE; DENGUE VIRUS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; INSTITUTE FOR CANCER RESEARCH MOUSE; JET INJECTION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PARALYSIS; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SECONDARY IMMUNE RESPONSE; STATISTICAL ANALYSIS; VERO CELL; VIREMIA; VIROGENESIS; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS TITRATION;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; DENGUE; DENGUE VACCINES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION, PASSIVE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; VIRAL LOAD; VIREMIA;

EID: 67349193209     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.083     Document Type: Article

References (48)

1. Green S., and Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19 (2006) 429-436
2. Gubler D.J., Kuno G., and Markoff L. Flaviviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 5th ed. (2007), Lippincott Williams & Willkins, Philadelphia 1153-1252
3. Halstead S.B. Dengue. Lancet 370 (2007) 1644-1652
4. Kurane I., and Takasaki T. Dengue fever and dengue haemorrhagic fever: challenges of controlling an enemy still at large. Rev Med Virol 11 (2001) 301-311
5. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10 (2002) 100-103
6. World Health Organization. Fact sheet N°117. Dengue and dengue haemorrhagic fever, http://www.who.int/mediacentre/factsheets/fs117/en/; 2008 [accessed 14 December 2008].
7. Edelman R., and Hombach J. "Guidelines for the clinical evaluation of dengue vaccines in endemic areas": Summary of a World Health Organization Technical Consultation. Vaccine 26 (2008) 4113-4119
8. Hatch S., Mathew A., and Rothman A. Dengue vaccine: opportunities and challenges. IDrugs 11 (2008) 42-45
9. Pierson T.C., and Diamond M.S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 10 (2008) e12
10. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181 (2000) 2-9
11. Libraty D.H., Endy T.P., Houng H.S., Green S., Kalayanarooj S., Suntayakorn S., et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185 (2002) 1213-1221
12. Stephenson J.R. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 83 (2005) 308-314
13. Weaver S.C. Host range, amplification and arboviral disease emergence. Arch Virol Suppl 19 (2005) 33-44
14. Yamada K., Takasaki T., Nawa M., and Kurane I. Virus isolation as one of the diagnostic methods for dengue virus infection. J Clin Virol 24 (2002) 203-209
15. Ooi Y., Hayashi A., Aoki H., Eda J., Hamada M., Imura S., et al. Viral titers in the sera of dengue patients among travellers at the quarantine station of Kansai International Airport. Jpn J Infect Dis 6 (2008) 329-330
16. Roehrig J.T., Hombach J., and Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21 (2008) 123-132
17. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74 (2000) 5477-5485
18. Blaney Jr. J.E., Sathe N.S., Hanson C.T., Firestone C.Y., Murphy B.R., and Whitehead S.S. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1. Virol J 4 (2007) 23
19. Chen L., Ewing D., Subramanian H., Block K., Rayner J., Alterson K.D., et al. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J Virol 81 (2007) 11634-11639
20. Bernardo L., Izquierdo A., Alvarez M., Rosario D., Prado I., López C., et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 80 (2008) 194-199
21. Bente D.A., and Rico-Hesse R. Models of dengue virus infection. Drug Discov Today Dis Models 3 (2006) 97-103
22. Yauch L.E., and Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res 80 (2008) 87-93
23. Schlesinger R.W. Dengue viruses. Virol Monogr 16 (1977) 1-132
24. Raut C.G., Deolankar R.P., Kolhapure R.M., and Goverdhan M.K. Susceptibility of laboratory-bred rodents to the experimental infection with dengue virus type 2. Acta Virol 40 (1996) 143-146
25. Paes M.V., Pinhao A.T., Barreto D.F., Costa S.M., Oliveira M.P., Nogueira A.C., et al. Liver injury and viremia in mice infected with dengue-2 virus. Virology 338 (2005) 236-246
26. Chen H.C., Lai S.Y., Sung J.M., Lee S.H., Lin Y.C., Wang W.K., et al. Lymphocyte activation and hepatic cellular infiltration in immunocompetent mice infected by dengue virus. J Med Virol 73 (2004) 419-431
27. Chen H.C., Hofman F.M., Kung J.T., Lin Y.D., and Wu-Hsieh B.A. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J Virol 81 (2007) 5518-5526
28. Huang K.J., Li S.Y., Chen S.C., Liu H.S., Lin Y.S., Yeh T.M., et al. Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J Gen Virol 81 (2000) 2177-2182
29. Wu S.J., Hayes C.G., Dubois D.R., Windheuser M.G., Kang Y.H., Watts D.M., et al. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection. Am J Trop Med Hyg 52 (1995) 468-476
30. Lin Y.L., Liao C.L., Chen L.K., Yeh C.T., Liu C.I., Ma S.H., et al. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J Virol 72 (1998) 9729-9737
31. An J., Kimura-Kuroda J., Hirabayashi Y., and Yasui K. Development of a novel mouse model for dengue virus infection. Virology 263 (1999) 70-77
32. Blaney Jr. J.E., Johnson D.H., Manipon G.G., Firestone C.Y., Hanson C.T., Murphy B.R., et al. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300 (2002) 125-139
33. Bente D.A., Melkus M.W., Garcia J.V., and Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J Virol 79 (2005) 13797-13799
34. -/- (RAG-hu) mice. Virology 369 (2007) 143-152
35. Johnson A.J., and Roehrig J.T. New mouse model for dengue virus vaccine testing. J Virol 73 (1999) 783-786
36. Shresta S., Sharar K.L., Prigozhin D.M., Beatty P.R., and Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80 (2006) 10208-10217
37. Chen S.T., Lin Y.L., Huang M.T., Wu M.F., Cheng S.C., Lei H.Y., et al. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 453 (2008) 672-676
38. Imoto J., and Konishi E. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine 25 (2007) 1076-1084
39. Lozzio C.B., and Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45 (1975) 321-334
40. Konishi E., and Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20 (2002) 1058-1067
41. Konishi E., Yamaoka M., Kurane I., and Mason P.W. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18 (2000) 1133-1139
42. Yamanaka A., Kosugi S., and Konishi E. Infection-enhancing-neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol 82 (2008) 927-937
43. Konishi E., Ajiro N., Nukuzuma C., Mason P.W., and Kurane I. Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymophocytes in mice. Vaccine 21 (2003) 3675-3683
44. Lee E., Pavy M., Young N., Freeman C., and Lobigs M. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res 69 (2006) 31-38
45. Prestwood T.R., Prigozhin D.M., Sharar K.L., Zellweger R.M., and Shresta S. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J Virol 82 (2008) 8411-8421
46. Hombach J., Solomon T., Kurane I., Jacobson J., and Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23 (2005) 5205-5211
47. Hombach J., Cardosa M.L., Sabchareon A., Vaughn D.W., and Barrett A.D. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 25 (2007) 4130-4139
48. Kyle J.L., Balsitis S.J., Zhang L., Beatty P.R., and Harris E. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 380 (2008) 296-303